Meibum Scientific: Investor Overview
Treating the Root Cause of Chronic Dry Eye
Meibum Scientific targets the biological mechanism driving chronic dry eye through a protocolized platform that removes intraglandular biofilm — the missing treatment target in meibomian gland dysfunction.
Investor Presentation
Dry Eye Is a Disease of Gland Failure
Chronic dry eye is driven primarily by meibomian gland dysfunction (MGD), a progressive condition in which obstruction and inflammation impair the eye's ability to produce stable tear film lipids. Existing approaches treat downstream symptoms but fail to address the biological process causing gland damage. Without removing the root cause, disease progresses toward irreversible gland atrophy.
A Large, Underserved Market
300M+
Global dry eye patients in Symptom Management
>70%
Driven by meibomian gland dysfunction (MGD)
~16M+
MGD-related U.S. eye-care visits annually
$10B+
U.S. dry eye market lacking durable solutions
Despite its scale, the market remains dominated by symptom management rather than disease-modifying treatment.
Why Current Therapies Fail
Drops and hygiene
Lubricate the surface but do not address obstruction
Heat, expression, and IPL
Provide temporary relief without removing adherent pathology
Pharmaceuticals
Reduce inflammation but do not penetrate intraglandular biofilm
Temporary relief masks ongoing gland destruction.
The Missing Treatment Target (Biofilm)
Biofilm is a polysaccharide-based bacterial matrix that forms both on the lid margin and inside the meibomian glands.
Within the glands, biofilm binds tightly to duct walls, sustaining chronic inflammation, obstructing meibum flow, and resisting heat, pressure, and pharmacologic penetration. As long as intraglandular biofilm remains, disease progression continues.
The REVVE™ Biofilm Elimination Platform
BlephEx® + OptiVize™ Deployed Through a Protocolized Workflow
Meibum Scientific delivers a mechanism-based platform designed to remove biofilm at every level of disease.
Platform Components
BlephEx®
The foundational step — removes lid-margin biofilm and inflammatory burden, preparing the glands for successful downstream therapy.
OptiVize™
The breakthrough step — the only technology designed to eliminate intraglandular biofilm, unlocking gland function inaccessible to heat, pressure, or pharmaceuticals.
REVVE™ Protocol Flow
1
Recognize
2
Exfoliate
3
Vaporize
4
Vibrate
5
Express
Drives consistent outcomes, repeatable workflows, and defensible adoption.
Validated in Real-World Clinical Practice
Real-world outcomes from routine clinical use of the REVVE™ protocol.
325+
Patients
treated
78%
Symptom improvement by month four
~7 sec
Improvement
in tear
break-up time
0
Adverse
events
The REVVE™ Biofilm Elimination Platform
PRE-TREATMENT
POST-TREATMENT
BlephEx® + OptiVize™ deployed through a protocoled workflow
Aligned Clinical and Economic Value
Patient Benefits
  • Improved tear stability and visual comfort
  • Reduced dependence on daily drops
  • Durable symptom improvement with maintenance care
Physician Benefits
  • Short, in-office procedures integrated into existing workflows
  • Cash-pay model independent of reimbursement
  • Recurring revenue through protocol-driven treatment cadence
  • Visible outcomes that reinforce adherence and engagement

Meibum Scientific Corporate Overview
For detailed financial projections, clinical data, regulatory pathway, and commercialization strategy, contact meibum@cg.capital to access the complete investor materials.